• 阻害剤の選択性比較
  • 溶解度
カタログ番号 製品カタログ 溶解度(25°C)
DMSO アルコール
S1049 Y-27632 2HCl 14 mg/mL 64 mg/mL <1 mg/mL
S1459 Thiazovivin <1 mg/mL 15 mg/mL <1 mg/mL
S1573 Fasudil (HA-1077) HCl 65 mg/mL 5 mg/mL <1 mg/mL
S1474 GSK429286A <1 mg/mL 87 mg/mL 4 mg/mL
S7195 RKI-1447 <1 mg/mL 65 mg/mL <1 mg/mL
S8489 GSK180736A (GSK180736) <1 mg/mL 73 mg/mL 3 mg/mL
S8208 Hydroxyfasudil (HA-1100) HCl 60 mg/mL 68 mg/mL <1 mg/mL
S7687 GSK269962 HCl <1 mg/mL 100 mg/mL 6 mg/mL
S8226 Netarsudil (AR-13324) 2HCl 54 mg/mL 20 mg/mL 2 mg/mL
S7935 Y-39983 HCl 63 mg/mL 63 mg/mL 2 mg/mL
S8448 ZINC00881524 (ROCK inhibitor) <1 mg/mL 76 mg/mL 3 mg/mL
S7936 KD025 (SLx-2119) <1 mg/mL 90 mg/mL <1 mg/mL
S7995 Ripasudil (K-115) hydrochloride dihydrate 79 mg/mL 26 mg/mL 5 mg/mL
S7563 AT13148 <1 mg/mL 62 mg/mL <1 mg/mL


製品コード 製品説明 文献中の使用例 お客様のフィードバック

Y-27632 2HCl

Y-27632 2HCl is a selective ROCK1 (p160ROCK) inhibitor with Ki of 140 nM in a cell-free assay, exhibits >200-fold selectivity over other kinases, including PKC, cAMP-dependent protein kinase, MLCK and PAK.



Thiazovivin is a novel ROCK inhibitor with IC50 of 0.5 μM in a cell-free assay, promotes hESC survival after single-cell dissociation.


Fasudil (HA-1077) HCl

Fasudil(HA-1077), a potent and selective inhibitor of Rho kinase, displays less potent inhibiton over PKA, PKG, PKC and MLCK with Ki of 1.6, 1.6, 3.3, and 36 μM in cell-free assays, respectively.



GSK429286A is a selective inhibitor of ROCK1 and ROCK2 with IC50 of 14 nM and 63 nM, respectively.



RKI-1447 is a potent inhibitor of ROCK1 and ROCK2, with IC50 of 14.5 nM and 6.2 nM, respectively, has anti-invasive and antitumor activities.


GSK180736A (GSK180736)

GSK180736A, developed as a Rho-associated, coiled-coil-containing protein kinase inhibitor, binds to GRK2(G protein-coupled receptor kinase 2) with logIC50 pf -6.6 (logIC50 -4.0 for GRK5 and >-3 for GRK1); ≥400-fold selective for GRK2 over both GRK1 and GRK5.


Hydroxyfasudil (HA-1100) HCl

Hydroxyfasudil (HA-1100), an active metabolite of fasudil hydrochloride, is a specific Rho-kinase(ROCK) inhibitor with IC50 values of 0.73 μM and 0.72 μM for ROCK1 and ROCK2, respectively.


GSK269962 HCl

GSK269962 is a selective ROCK(Rho-associated protein kinase) inhibitor with IC50 values of 1.6 and 4 nM for ROCK1 and ROCK2, respectively.


Netarsudil (AR-13324) 2HCl

Netarsudil (a.k.a. AR-13324) is ROCK inhibitor with Ki value of 0.2-10.3 nM. It is currently in clinical trials for the treatment of glaucoma and ocular hypertension.


Y-39983 HCl

Y-39983 is a selective rho-associated protein kinase(ROCK) inhibitor with an IC50 of 3.6 nM.


ZINC00881524 (ROCK inhibitor)

ZINC00881524 is a ROCK inhibitor.


KD025 (SLx-2119)

KD025 is an orally available, and selective ROCK2 inhibitor with IC50 and Ki of 60 nM and 41 nM, respectively. Phase 2.


Ripasudil (K-115) hydrochloride dihydrate

Ripasudil (K-115) hydrochloride dihydrate is potent ROCK inhibitor with IC50 of 51 nM and 19 nM for ROCK1 and ROCK2, respectively, used for the treatment of glaucoma and ocular hypertension.



AT13148 is an oral, ATP-competitive, multi-AGC kinase inhibitor with IC50 of 38 nM/402 nM/50 nM, 8 nM, 3 nM, and 6 nM/4 nM for Akt1/2/3, p70S6K, PKA, and ROCKI/II, respectively. Phase 1.

Tags: ROCK inhibition | ROCK activity | ROCK activation | Rho kinase inhibition | Rho kinase activation | Rho kinase activity | ROCK phosphorylation | ROCK signaling pathway | Rho kinase assay | Rho kinase signaling pathway | ROCK inhibitors for glaucoma | ROCK inhibitor review